Personalized Medicine - Translational Informatics: Realizing the Promise of Knowledge-Driven Healthcare - page 54

4. NHGRI. DNA sequencing costs. 2013. [9/17/2013]. Available from: http://www.genome.gov/
sequencingcosts/ .
5. Herper M. The $1,000 genome arrives - for real, this time. Forbes [serial on the Internet]. 2014.
Available from: http://www.forbes.com/sites/matthewherper/2014/01/14/the-1000-genome-
arrives-for-real-this-time/ .
6. Schadt EE, Turner S, Kasarskis A. A window into third-generation sequencing. Hum Mol
Genet. 2010;19(R2):R227-40.
7. NRC. Toward precision medicine: building a knowledge network for biomedical research and
a new taxonomy of disease. 2011.
8. Hood L. Systems biology and p4 medicine: past, present, and future. Rambam Maimonides
Med J. 2013;4(2):e0012.
9. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics.
Nature. 2004;429(6990):464-8.
10. Burrill GS. Where's the beef? Drug Discov. 2003;4:9.
11. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside.
Nature. 2011;470(7333):204-13.
12. Trusheim MR, Berndt ER, Douglas FL. Stratifi ed medicine: strategic and economic implica-
tions of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287-93.
13. Shortliffe EH, Cimino JJ. Medical informatics: computer applications in health care and bio-
medicine. London: Springer; 2013.
14. Killion PJ, Sherlock G, Iyer VR. The Longhorn Array Database (LAD): an open-source, MIAME
compliant implementation of the Stanford Microarray Database (SMD). BMC Bioinforma.
2003;4:32.
15. Nuzzo R. Scientifi c method: statistical errors. Nature. 2014;506(7487):150-2.
16. CDC. [9/10/2013]. Available from: http://www.cdc.gov/genomics/gtesting/ACCE/ .
17. Ginsburg GS, Woods CW. The host response to infection: advancing a novel diagnostic para-
digm. Crit Care. 2012;16(6):168.
18. Hecker, Michael, et al. Reassessment of blood gene expression markers for the prognosis of
relapsing-remitting multiple sclerosis. PloS one. 2011;6(12):e29648.
19. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al. Application of bio-
markers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr
Cartil. 2011;19(5):515-42.
20. Voils CI, Coffman CJ, Edelman D, Maciejewski ML, Grubber JM, Sadeghpour A, et al.
Examining the impact of genetic testing for type 2 diabetes on health behaviors: study protocol
for a randomized controlled trial. Trials. 2012;13:121.
21. Butte AJ. Translational bioinformatics: coming of age. J Am Med Inform Assoc. 2008;
15(6):709-14.
22. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through
whole-genome sequencing. Nat Rev Genet. 2010;11(6):415-25.
23. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized
trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294-303.
24. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacoge-
netic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283-93.
25. Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fi brosis and the G551D-CFTR
mutation. Eur Respir Rev. 2013;22(127):66-71.
26. O'Bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for
ALK-positive non-small cell lung cancer. Ann Pharmacother. 2013;47(2):189-97.
27. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the fi rst drug
approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873-86.
28. Annas GJ, Elias S. 23andMe and the FDA. N Engl J Med. 2014;370(11):985-8.
29. Johnson M, Gallagher K. Living on the edge of science. Journal Sentinel. 2012. 6/30/2012.
30. Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, Newsham I, et al.
Whole-genome sequencing for optimized patient management. Sci Transl Med. 2011;3(87):87re3.